Structure Therapeutics (NASDAQ:GPCR) Trading 6% Higher – What’s Next?

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) were up 6% on Wednesday . The company traded as high as $21.99 and last traded at $22.39. Approximately 59,438 shares traded hands during trading, a decline of 93% from the average daily volume of 838,890 shares. The stock had previously closed at $21.11.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. William Blair started coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating on the stock. Stifel Nicolaus started coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. Finally, JMP Securities reissued a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics presently has an average rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Stock Up 8.4 %

The business’s fifty day moving average is $25.08 and its 200 day moving average is $32.09. The stock has a market cap of $1.31 billion, a PE ratio of -31.16 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. As a group, analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in GPCR. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Structure Therapeutics in the 4th quarter valued at about $3,091,000. GF Fund Management CO. LTD. purchased a new stake in shares of Structure Therapeutics in the fourth quarter valued at about $34,000. Woodline Partners LP grew its position in shares of Structure Therapeutics by 0.7% in the fourth quarter. Woodline Partners LP now owns 333,901 shares of the company’s stock valued at $9,055,000 after purchasing an additional 2,328 shares during the last quarter. Vestal Point Capital LP increased its stake in shares of Structure Therapeutics by 50.0% during the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $46,782,000 after purchasing an additional 575,000 shares in the last quarter. Finally, Twinbeech Capital LP raised its position in shares of Structure Therapeutics by 34.3% during the 4th quarter. Twinbeech Capital LP now owns 28,268 shares of the company’s stock worth $767,000 after purchasing an additional 7,220 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.